BPC-157 ARG + TB-4 FRAG - 10ml/30mg + 30mg - Spray

ADVANCED DELIVERY SYSTEM - CELL PENETRATING PEPTIDE TECHNOLOGY

This product utilizes advanced delivery technology incorporating calibrated cell-penetrating peptide (CPP) systems. The formulation is engineered to support efficient and targeted intracellular delivery of active ingredients, contributing to enhanced transport performance and bioavailability.

SPECIFICATIONS

Product Code: BPTB10S

BPC-157 ARGINATE FORM – 30 mg

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val × 2 × L-Arg

Molecular Formula: C62H98N16O22

Molecular Weight (peptide base): 1418.70 g/mol

CAS: 137525-51-0

Purity: Technical / Research Grade ≥98%

THYMOSIN BETA-4 FRAGMENT - 30 mg

Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln

Molecular Formula: C38H68N10O14

Molecular Weight: 889.018 g/mol

CAS number: 885340-08-9

Purity: Technical / Research Grade ≥98%

General Properties

Other details: No TFA Salt

Form: Liquid Solution

Color: Clear / Slightly opalescent

Total Content: 60 mg in 10 mL (6 mg/mL total peptide concentration)

Per mL:

BPC-157 Arginate – 3 mg

Thymosin Beta-4 Fragment – 3 mg

Approximate Sprays per Bottle: ~82

Approximate Peptide per Spray: BPC-157 Arginate ~365 mcg; Thymosin Beta-4 (43AA) ~365 mcg

Vehicle / Carrier System: Proprietary carrier system

Storage Temperature: 4°C (Do not freeze)

Source: Synthetic

Safety classification: Standard laboratory handling

DESCRIPTION

BPC-157 ARGINATE FORM

BPC-157 is a synthetic peptide derived from a sequence naturally present in gastric juice, where endogenous BPC peptides are involved in maintaining gastrointestinal mucosal integrity. In preclinical research models, BPC-157 has been used to investigate mechanisms related to epithelial barrier stability, extracellular matrix organization, and tissue repair signaling under experimental conditions.

Fibroblast Activity and Extracellular Matrix Research

In cell culture systems and animal models, BPC-157 has been studied for its influence on fibroblast proliferation and migration, two key cellular processes involved in wound healing and connective tissue remodeling.

Angiogenesis and Ischemia-Related Models

BPC-157 has been investigated in preclinical angiogenesis assays to explore its effects on endothelial cell behavior and collateral vessel formation in gastrointestinal, cardiovascular, neural, and musculoskeletal research contexts.

Musculoskeletal and Connective Tissue Research

In in vitro and in vivo models of tendon, ligament, and bone injury, BPC-157 has been examined for its role in cell recruitment, vascular density, and connective tissue organization under laboratory conditions.

Oxidative Stress and Inflammatory Signaling Models

In rodent models, BPC-157 has been studied for its interaction with oxidative stress markers, including pathways involving nitric oxide signaling and lipid peroxidation indices.

Neurobiology and Brain–Gut Axis Research

Experimental studies have examined BPC-157 in neurobiological models to explore interactions between peripheral tissues and central signaling pathways, including serotonergic and dopaminergic systems.

THYMOSIN BETA-4 FRAGMENT

Thymosin Beta-4 Fragment, also referred to as TB-500 in research contexts, is a peptide widely used in preclinical research models to study cell migration, cytoskeletal dynamics, and tissue repair mechanisms.

Actin Regulation and Cell Migration

Tβ4 interacts with G-actin, influencing cytoskeletal organization and cell motility in keratinocytes, endothelial cells, and fibroblasts.

Angiogenesis and Tissue Repair Models

Tβ4 has been extensively studied in angiogenesis assays and wound-healing models involving cutaneous, corneal, muscular, and cardiac experimental systems.

Inflammatory Signaling Research

In animal models, Tβ4 has been investigated for modulation of cytokine-associated signaling pathways, including NF-κB activity and matrix metalloproteinase expression.

Cardiovascular and Neurological Research Models

Tβ4 has been included in preclinical myocardial injury and neurological models to explore cell survival, migration, and tissue remodeling pathways.

REFERENCES

All information presented above is derived from in vitro experiments, animal studies, and other preclinical research models. These data are intended solely for basic scientific investigation and do not imply therapeutic, diagnostic, or preventive applications in humans or animals.

A. Goldstein et al., "Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications" [PubMed]

A. Goldstein et al., "Advances in the basic and clinical applications of thymosin β4" [PubMed]

D. Crockford et al., "Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications" [PubMed]

G. Sosne et al., "Biological activities of thymosin beta4 defined by active sites in short peptide sequences" [PubMed]

E.G. Yarmola et al., "Thymosin beta4: actin regulation and more" [PubMed]

M. Badamchian et al., "Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock" [PubMed]

A. Gonzales-Franquesa et al., "Discovery of thymosin β4 as a human exerkine and growth factor" [PubMed]

J.D. Young et al., "Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids" [PubMed]

M.R. Bubb, "Thymosin beta 4 interactions" [PubMed]

Y. Xing et al., "Progress on the Function and Application of Thymosin β4" [PubMed]

DISCLAIMER

This product is intended for laboratory research and development use only. It is not a medicine or drug and has not been approved by the FDA or EMA to prevent, treat, or cure any disease. Bodily introduction into humans or animals is strictly prohibited. This product must be handled by qualified research professionals.

All product information provided is for informational and educational purposes only.